Welcome to our dedicated page for Ptc Therapeutics news (Ticker: PTCT), a resource for investors and traders seeking the latest updates and insights on Ptc Therapeutics stock.
PTC Therapeutics, Inc. (NASDAQ: PTCT) is a global biopharmaceutical company focused on clinically differentiated medicines for children and adults living with rare disorders. The PTCT news feed on Stock Titan aggregates company announcements, financial updates and regulatory milestones that PTC discloses through press releases and SEC filings.
Investors following PTCT news can see updates on the commercial performance and global rollout of products such as Sephience (sepiapterin) for phenylketonuria (PKU), as well as revenue contributions from the company’s Duchenne muscular dystrophy franchise, which includes Translarna (ataluren) and Emflaza (deflazacort). News items also cover royalty revenue from Evrysdi (risdiplam) and changes in royalty arrangements, such as the sale of certain Evrysdi royalty rights to Royalty Pharma.
PTC Therapeutics regularly reports quarterly and annual financial results, including total revenue, product revenue, royalty and collaboration revenue, and details on GAAP and non-GAAP R&D and SG&A expenses. Corporate updates often highlight pipeline and regulatory developments, including FDA meetings for programs like votoplam in Huntington’s disease and vatiquinone in Friedreich’s ataxia, as well as ongoing review of the Translarna NDA.
The company also issues news about regulatory approvals and launches in different regions, such as Sephience approvals in the EU, US and Japan, and about R&D-focused events and investor conference presentations. In addition, PTC discloses equity inducement grants under Nasdaq Listing Rule 5635(c)(4), illustrating its use of stock options and restricted stock units as part of employee compensation.
By monitoring the PTCT news page, readers can track how product launches, regulatory decisions, collaborations, royalty transactions and capital markets activities shape the company’s progress in the rare disease biopharmaceutical sector.
PTC Therapeutics (NASDAQ: PTCT) announced inducement equity grants approved Nov. 24, 2025, to 15 new employees under Nasdaq Listing Rule 5635(c)(4).
The company approved non-statutory stock options to purchase an aggregate of 2,000 shares and 8,200 restricted stock units (RSUs). Options have an exercise price of $79.83 (closing price on Nov. 24, 2025), a 10-year term, and vest over four years: 25% at first anniversary then 6.25% each subsequent three months. RSUs vest over four years with 25% on each annual anniversary. Grants were approved by the Compensation Committee and issued as inducements material to each hire's acceptance of employment.
PTC Therapeutics (NASDAQ: PTCT) will host an R&D Day on Dec. 2, 2025 at 9:30 a.m. EST in New York City, with a live webcast and replay available for ~30 days.
CEO Matthew B. Klein, M.D., and R&D leaders will present updates on the company’s proprietary small molecule splicing and inflammation platforms, including new targets and programs. Investors can register and access the webcast via the Events and Presentations page in the company’s Investor website.
PTC Therapeutics (NASDAQ: PTCT) reported Q3 2025 total revenue of $211.0M and positive net income of $15.9M. The company initiated the global launch of Sephience (sepiapterin), recording $19.6M in Sephience revenue, 521 US patient start forms from 141 prescribers, and 341 patients on commercial therapy worldwide as of September 30, 2025.
Third-quarter product revenue was $131.0M with royalty and collaboration revenue of $80.1M (including $70.8M royalty from Evrysdi). Cash, cash equivalents and marketable securities were $1.688B at quarter end. PTC narrowed full-year 2025 revenue guidance to $750–$800M and projects GAAP R&D and SG&A of $805–$835M (non-GAAP $730–$760M).
PTC Therapeutics (NASDAQ: PTCT) announced executive presentations at three investor conferences: UBS Global Healthcare Conference on Nov 11, 2025 at 3:30 p.m. EST, Jefferies Global Healthcare Conference on Nov 18, 2025 at 8:00 a.m. GMT / 3:00 a.m. EST, and Citi 2025 Global Healthcare Conference on Dec 4, 2025 at 10:30 a.m. EST.
All presentations will be webcast live and archived for 30 days on PTC's Investor Events and Presentations page. Users are advised to connect to the webcast several minutes early to ensure a timely connection.
PTC Therapeutics (NASDAQ: PTCT) announced inducement equity grants approved Oct. 23, 2025 for two new employees under Nasdaq Listing Rule 5635(c)(4).
The company granted non-statutory stock options to purchase an aggregate of 2,000 shares and 1,990 restricted stock units (RSUs). Options have an exercise price of $66.80 (closing price on Oct. 23, 2025), a 10-year term, and vest over four years: 25% at the first anniversary then 6.25% quarterly thereafter. RSUs vest over four years with 25% vesting on each annual anniversary. Grants were approved by the Compensation Committee and made as inducements to accept employment.
PTC Therapeutics (NASDAQ: PTCT) will host a webcast conference call to report third quarter 2025 financial results and provide a business outlook on Tuesday, November 4, 2025 at 4:30 p.m. ET.
Participants can register for phone access to receive dial-in details and are advised to dial in 15 minutes early. The live webcast will be available in the Investors section at https://ir.ptcbio.com/events-presentations. A replay will be posted about two hours after the call and will remain archived on the company website for 30 days.
PTC Therapeutics (NASDAQ: PTCT) announced the approval of equity compensation awards for 48 new employees. The company granted 19,475 non-statutory stock options at an exercise price of $58.99 per share and 39,060 restricted stock units (RSUs).
The stock options have a 10-year term with a 4-year vesting schedule: 25% vesting after one year and 6.25% quarterly thereafter. The RSUs also vest over four years, with 25% vesting annually. These inducement grants were approved by PTC's Compensation Committee under Nasdaq Listing Rule 5635(c)(4) as part of new hire compensation packages.
PTC Therapeutics (NASDAQ: PTCT) has announced its participation in three major healthcare investor conferences in September 2025. The company will present at the Cantor Global Healthcare Conference on September 3 at 8:35 a.m. ET, the Wells Fargo Healthcare Conference on September 4 at 11:00 a.m. ET, and the Morgan Stanley Global Healthcare Conference on September 8 at 9:15 a.m. ET.
All presentations will be available via webcast on PTC's investor relations website and will remain accessible for 30 days after each event.
PTC Therapeutics (NASDAQ: PTCT) has received a Complete Response Letter (CRL) from the FDA regarding its New Drug Application (NDA) for vatiquinone, intended to treat Friedreich's ataxia in children and adults.
The FDA determined that substantial evidence of efficacy was not demonstrated for vatiquinone and stated that an additional adequate and well-controlled study would be required to support NDA resubmission. CEO Matthew B. Klein expressed disappointment with the FDA's decision and indicated the company plans to meet with the FDA to address the issues raised in the CRL.
PTC Therapeutics (NASDAQ:PTCT) reported Q2 2025 financial results and corporate updates. The quarter was marked by the European and FDA approval of Sephience™ for PKU treatment with broad labeling. Total revenue reached $178.9 million, including $96 million from the DMD franchise. The company reported a net loss of $64.8 million, improved from $99.2 million in Q2 2024.
Key highlights include cash position of $1.99 billion, positive Phase 2 PIVOT-HD study results for votoplam in Huntington's Disease, and ongoing NDA reviews for vatiquinone and Translarna. PTC updated its full-year 2025 revenue guidance to $650-800 million.
The company entered an agreement to purchase Sephience's annual sales obligation for $225 million upfront plus future milestone payments.